Advaxis Stock Price, News & Analysis (NASDAQ:ADXS)

$2.99 0.14 (4.91 %)
(As of 12/11/2017 08:13 AM ET)
Previous Close$2.85
Today's Range$2.85 - $3.00
52-Week Range$2.71 - $10.06
Volume533,600 shs
Average Volume690,237 shs
Market Capitalization$122.79 million
P/E RatioN/A
Dividend YieldN/A
Beta1.95

About Advaxis (NASDAQ:ADXS)

Advaxis logoAdvaxis, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-LLO strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Axalimogene filolisbac is its lead Lm-LLO immunotherapy product candidate for the treatment of Human Papilloma Virus-associated cancers. ADXS-PSA is its Lm-LLO immunotherapy product candidate that targets the Prostate Specific Antigen (PSA) associated with prostate cancer.

Receive ADXS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADXS
CUSIPN/A
Phone609-452-9813

Debt

Debt-to-Equity RatioN/A
Current Ratio4.60%
Quick Ratio4.60%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.99 million
Price / Sales30.78
Cash FlowN/A
Price / CashN/A
Book Value$2.99 per share
Price / Book1.00

Profitability

Trailing EPS($2.29)
Net Income$-73,550,000.00
Net Margins-655.66%
Return on Equity-93.54%
Return on Assets-64.49%

Miscellaneous

Employees90
Outstanding Shares41,070,000

Advaxis (NASDAQ:ADXS) Frequently Asked Questions

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) announced its earnings results on Monday, September, 11th. The biotechnology company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.53) by $0.27. The biotechnology company earned $3.05 million during the quarter, compared to analyst estimates of $3.43 million. Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. View Advaxis' Earnings History.

When will Advaxis make its next earnings announcement?

Advaxis is scheduled to release their next quarterly earnings announcement on Tuesday, January, 16th 2018. View Earnings Estimates for Advaxis.

Where is Advaxis' stock going? Where will Advaxis' stock price be in 2017?

2 brokerages have issued 12-month price objectives for Advaxis' shares. Their predictions range from $19.00 to $23.00. On average, they anticipate Advaxis' stock price to reach $21.00 in the next twelve months. View Analyst Ratings for Advaxis.

Who are some of Advaxis' key competitors?

Who are Advaxis' key executives?

Advaxis' management team includes the folowing people:

  • David Sidransky M.D., Independent chairman of the Board of Director (Age 56)
  • Anthony Lombardo, Interim Chief Executive Officer (Age 70)
  • Sara M. Bonstein, Chief Financial Officer, Executive Vice President (Age 36)
  • Robert G. Petit Ph.D., Executive Vice President, Chief Scientific Officer (Age 57)
  • James P. Patton M.D., Non-Executive Independent Vice Chairman of the Board (Age 59)
  • Gregory T. Mayes III, Director (Age 48)
  • Roni A. Appel, Independent Director (Age 50)
  • Richard J. Berman J.D., Independent Director (Age 73)
  • Samir N. Khleif, Independent Director (Age 53)

Who owns Advaxis stock?

Advaxis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include ADAGE CAPITAL PARTNERS GP, L.L.C. (11.45%), D.A. Davidson & CO. (0.16%), Cutler Capital Management LLC (0.12%) and Stonebridge Capital Management Inc. (0.10%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Daniel O'connor, David Sidransky, Gregory T Mayes, Richard J Berman, Robert Petit, Sara Bonstein and Thomas J Mckearn. View Institutional Ownership Trends for Advaxis.

Who sold Advaxis stock? Who is selling Advaxis stock?

Advaxis' stock was sold by a variety of institutional investors in the last quarter, including D.A. Davidson & CO.. Company insiders that have sold Advaxis company stock in the last year include Adage Capital Partners Gp, LL, Anthony A Lombardo, Robert Petit, Sara Bonstein and Thomas J Mckearn. View Insider Buying and Selling for Advaxis.

Who bought Advaxis stock? Who is buying Advaxis stock?

Advaxis' stock was purchased by a variety of institutional investors in the last quarter, including Cutler Capital Management LLC and Stonebridge Capital Management Inc.. View Insider Buying and Selling for Advaxis.

How do I buy Advaxis stock?

Shares of Advaxis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Advaxis' stock price today?

One share of Advaxis stock can currently be purchased for approximately $2.99.

How big of a company is Advaxis?

Advaxis has a market capitalization of $122.79 million and generates $3.99 million in revenue each year. The biotechnology company earns $-73,550,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis. Advaxis employs 90 workers across the globe.

How can I contact Advaxis?

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]


MarketBeat Community Rating for Advaxis (ADXS)

Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  200 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  263
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Advaxis (NASDAQ:ADXS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.00$24.00$24.00$23.67
Price Target Upside: 668.00% upside668.00% upside258.21% upside249.58% upside

Advaxis (NASDAQ:ADXS) Consensus Price Target History

Price Target History for Advaxis (NASDAQ:ADXS)

Advaxis (NASDAQ:ADXS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/8/2017HC WainwrightReiterated RatingBuy$23.00N/AView Rating Details
9/25/2017Cantor FitzgeraldReiterated RatingBuy$19.00HighView Rating Details
9/9/2016Jefferies GroupReiterated RatingBuy$24.00N/AView Rating Details
8/3/2016BarclaysBoost Price TargetOverweight$15.00 -> $20.00N/AView Rating Details
7/7/2016FBR & CoReiterated RatingOutperform$34.00N/AView Rating Details
12/17/2015Janney Montgomery ScottReiterated RatingBuy$22.00N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Advaxis (NASDAQ:ADXS) Earnings History and Estimates Chart

Earnings by Quarter for Advaxis (NASDAQ:ADXS)

Advaxis (NASDAQ ADXS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/16/2018($0.55)N/AView Earnings Details
9/11/2017Q3($0.53)($0.80)$3.43 million$3.05 millionViewN/AView Earnings Details
3/10/2017Q1 2017($0.52)($0.43)$2.15 million$3.79 millionViewN/AView Earnings Details
6/8/2016Q2 2016($0.54)($0.45)$0.13 millionViewN/AView Earnings Details
3/13/2015Q1 2015($0.31)($0.33)ViewN/AView Earnings Details
6/9/2014Q3 2014($0.25)($0.30)$1.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Advaxis (NASDAQ:ADXS) Earnings Estimates

2017 EPS Consensus Estimate: ($2.30)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.51)($0.51)($0.51)
Q2 20171($0.54)($0.54)($0.54)
Q3 20171($0.61)($0.61)($0.61)
Q4 20171($0.64)($0.64)($0.64)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Advaxis (NASDAQ:ADXS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Advaxis (NASDAQ ADXS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.21%
Institutional Ownership Percentage: 41.90%
Insider Trades by Quarter for Advaxis (NASDAQ:ADXS)
Institutional Ownership by Quarter for Advaxis (NASDAQ:ADXS)

Advaxis (NASDAQ ADXS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/6/2017Robert PetitInsiderSell3,723$3.30$12,285.90View SEC Filing  
11/6/2017Sara BonsteinCFOSell3,862$3.30$12,744.60View SEC Filing  
11/2/2017Anthony A LombardoCEOSell24$3.19$76.56View SEC Filing  
11/2/2017Robert PetitInsiderSell12,625$3.19$40,273.75View SEC Filing  
11/2/2017Sara BonsteinCFOSell12,734$3.19$40,621.46View SEC Filing  
10/11/2017Adage Capital Partners Gp, L.LMajor ShareholderSell600,000$4.30$2,580,000.00View SEC Filing  
9/26/2017Adage Capital Partners Gp, L.LMajor ShareholderSell1,239,323$4.42$5,477,807.66View SEC Filing  
3/31/2017Robert PetitInsiderSell2,454$8.24$20,220.96View SEC Filing  
12/30/2016Sara BonsteinCFOSell5,520$7.37$40,682.40View SEC Filing  
12/20/2016Thomas J MckearnDirectorSell12,316$8.08$99,513.28View SEC Filing  
11/2/2016Daniel O'connorCEOSell8,240$8.32$68,556.80View SEC Filing  
11/2/2016Robert PetitInsiderSell2,797$8.32$23,271.04View SEC Filing  
10/25/2016Gregory T MayesInsiderSell19,162$8.23$157,703.26View SEC Filing  
8/9/2016David SidranskyDirectorSell22,808$15.01$342,348.08View SEC Filing  
8/8/2016Richard J BermanDirectorSell18,000$15.21$273,780.00View SEC Filing  
5/13/2016Thomas J MckearnDirectorSell4,100$7.45$30,545.00View SEC Filing  
5/2/2016Daniel O'connorCEOSell8,237$7.51$61,859.87View SEC Filing  
5/2/2016Robert PetitInsiderSell2,785$7.51$20,915.35View SEC Filing  
3/31/2016Robert PetitInsiderSell3,325$9.13$30,357.25View SEC Filing  
3/16/2016Thomas J MckearnDirectorSell14,000$8.25$115,500.00View SEC Filing  
2/24/2016Sara BonsteinCFOSell15,037$5.58$83,906.46View SEC Filing  
1/29/2016Daniel O'connorCEOSell8,818$6.88$60,667.84View SEC Filing  
1/29/2016Robert PetitinsiderSell3,099$6.88$21,321.12View SEC Filing  
10/26/2015Gregory T MayesCOOSell19,231$11.63$223,656.53View SEC Filing  
10/20/2015David J MauroInsiderSell24,586$10.08$247,826.88View SEC Filing  
8/24/2015Adage Capital Partners Gp LlcMajor ShareholderBuy300,000$14.15$4,245,000.00View SEC Filing  
4/30/2015Adage Capital Partners Gp LlcMajor ShareholderBuy500,000$19.00$9,500,000.00View SEC Filing  
2/18/2015Adage Capital Partners Gp LlcMajor ShareholderBuy684,762$7.50$5,135,715.00View SEC Filing  
5/9/2014Richard J BermanDirectorSell14,530$2.63$38,213.90View SEC Filing  
3/31/2014Daniel O'connorCEOBuy3,333$3.00$9,999.00View SEC Filing  
10/24/2013Daniel O'connorCEOBuy13,500$4.00$54,000.00View SEC Filing  
10/24/2013Mark J RosenblumCFOBuy12,000$4.00$48,000.00View SEC Filing  
10/24/2013Robert PetitInsiderBuy12,800$4.00$51,200.00View SEC Filing  
10/24/2013Roni AppelDirectorBuy12,500$4.00$50,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Advaxis (NASDAQ ADXS) News Headlines

Source:
DateHeadline
Quotidian Technical Highlights on Selected Biotech Stocks -- Advaxis, Grifols, Juno Therapeutics, and Lexicon Pharma - PR Newswire (press release)Quotidian Technical Highlights on Selected Biotech Stocks -- Advaxis, Grifols, Juno Therapeutics, and Lexicon Pharma - PR Newswire (press release)
www.prnewswire.com - November 27 at 7:55 AM
Reviewing Advaxis (ADXS) and Its PeersReviewing Advaxis (ADXS) and Its Peers
www.americanbankingnews.com - November 27 at 3:18 AM
Analysis: Positioning to Benefit within Diebold, Liberty TripAdvisor, Paycom Software, First American, Advaxis, and Sanmina — Research Highlights Growth, Revenue, and Consolidated ResultsAnalysis: Positioning to Benefit within Diebold, Liberty TripAdvisor, Paycom Software, First American, Advaxis, and Sanmina — Research Highlights Growth, Revenue, and Consolidated Results
finance.yahoo.com - November 22 at 4:08 PM
Advaxis to Present at the Jefferies 2017 London Healthcare Conference - Business Wire (press release)Advaxis to Present at the Jefferies 2017 London Healthcare Conference - Business Wire (press release)
www.businesswire.com - November 9 at 9:36 PM
Advaxis to Present at the Jefferies 2017 London Healthcare ConferenceAdvaxis to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 9 at 4:28 PM
Advaxis (ADXS) "Buy" Rating Reaffirmed at HC WainwrightAdvaxis' (ADXS) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - November 8 at 11:10 PM
Advaxis, Inc. (ADXS) CFO Sara Bonstein Sells 3,862 SharesAdvaxis, Inc. (ADXS) CFO Sara Bonstein Sells 3,862 Shares
www.americanbankingnews.com - November 6 at 8:23 PM
Advaxis, Inc. (ADXS) Insider Robert Petit Sells 3,723 SharesAdvaxis, Inc. (ADXS) Insider Robert Petit Sells 3,723 Shares
www.americanbankingnews.com - November 6 at 8:22 PM
Advaxis, Inc. (ADXS) Insider Robert Petit Sells 12,625 SharesAdvaxis, Inc. (ADXS) Insider Robert Petit Sells 12,625 Shares
www.americanbankingnews.com - November 2 at 8:54 PM
Advaxis, Inc. (ADXS) CFO Sara Bonstein Sells 12,734 SharesAdvaxis, Inc. (ADXS) CFO Sara Bonstein Sells 12,734 Shares
www.americanbankingnews.com - November 2 at 8:54 PM
Advaxis to Receive $4.5 Million through the New Jersey Economic Development Authority NOL Program - Business Wire (press release)Advaxis to Receive $4.5 Million through the New Jersey Economic Development Authority NOL Program - Business Wire (press release)
www.businesswire.com - November 1 at 3:49 PM
Advaxis to Receive $4.5 Million through the New Jersey Economic Development Authority NOL ProgramAdvaxis to Receive $4.5 Million through the New Jersey Economic Development Authority NOL Program
finance.yahoo.com - November 1 at 3:49 PM
Advaxis: So Its Panic, Then? Where This Thing Is Headed - Seeking AlphaAdvaxis: So It's Panic, Then? Where This Thing Is Headed - Seeking Alpha
seekingalpha.com - October 30 at 3:56 PM
Analyzing Advaxis (ADXS) & Its RivalsAnalyzing Advaxis (ADXS) & Its Rivals
www.americanbankingnews.com - October 29 at 3:08 AM
Advaxis, Inc. (ADXS) Major Shareholder Adage Capital Partners Gp, L.L Sells 600,000 SharesAdvaxis, Inc. (ADXS) Major Shareholder Adage Capital Partners Gp, L.L Sells 600,000 Shares
www.americanbankingnews.com - October 12 at 4:12 PM
Short Interest Decreases By 15.8% For ADXSShort Interest Decreases By 15.8% For ADXS
www.thestreet.com - October 11 at 9:27 PM
Head-To-Head Review: Advaxis (ADXS) vs. Zynerba Pharmaceuticals (ZYNE)Head-To-Head Review: Advaxis (ADXS) vs. Zynerba Pharmaceuticals (ZYNE)
www.americanbankingnews.com - October 5 at 4:30 AM
Earnings Review and Free Research Report: Advaxis Reported its Q3 FY17 ResultsEarnings Review and Free Research Report: Advaxis Reported its Q3 FY17 Results
finance.yahoo.com - October 3 at 3:18 PM
Insiders Roundup: Twitter, McKesson Make Biggest TradesInsiders Roundup: Twitter, McKesson Make Biggest Trades
finance.yahoo.com - September 30 at 1:43 PM
Advaxis, Inc. (ADXS) Major Shareholder Adage Capital Partners Gp, L.L Sells 1,239,323 SharesAdvaxis, Inc. (ADXS) Major Shareholder Adage Capital Partners Gp, L.L Sells 1,239,323 Shares
www.americanbankingnews.com - September 26 at 7:24 PM
Advaxis, Inc. (ADXS) Rating Reiterated by Cantor FitzgeraldAdvaxis, Inc. (ADXS) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - September 25 at 4:06 PM
Advaxis to Webcast Company Overview at the Cantor Fitzgerald Global Healthcare ConferenceAdvaxis to Webcast Company Overview at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 23 at 9:33 AM
3 Things In Biotech You Should Learn Today: September 20, 2017 - Seeking Alpha3 Things In Biotech You Should Learn Today: September 20, 2017 - Seeking Alpha
seekingalpha.com - September 20 at 3:26 PM
Two Abstracts Featuring Advaxis’ Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer (SITC) MeetingTwo Abstracts Featuring Advaxis’ Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer (SITC) Meeting
finance.yahoo.com - September 19 at 3:33 PM
Corporate News Blog - EMA Grants Positive CHMP Opinion to Tesaro’s Ovarian Cancer DrugCorporate News Blog - EMA Grants Positive CHMP Opinion to Tesaro’s Ovarian Cancer Drug
finance.yahoo.com - September 18 at 3:57 PM
Advaxis to Present at Cantor Fitzgerald Global Healthcare ConferenceAdvaxis to Present at Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 18 at 3:57 PM
Cantor Fitzgerald Equities Analysts Decrease Earnings Estimates for Advaxis, Inc. (ADXS)Cantor Fitzgerald Equities Analysts Decrease Earnings Estimates for Advaxis, Inc. (ADXS)
www.americanbankingnews.com - September 18 at 3:42 AM
Advaxis, Inc. (ADXS) Rating Reiterated by HC WainwrightAdvaxis, Inc. (ADXS) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - September 15 at 4:52 PM
Relative Strength Alert For AdvaxisRelative Strength Alert For Advaxis
www.thestreet.com - September 13 at 4:18 PM
Todays Research Reports on Stocks to Watch: Advaxis and Heat BiologicsToday's Research Reports on Stocks to Watch: Advaxis and Heat Biologics
finance.yahoo.com - September 13 at 4:18 PM
Where Do The Chips Fall For Advaxis Going Into Q4 2017? - Seeking AlphaWhere Do The Chips Fall For Advaxis Going Into Q4 2017? - Seeking Alpha
seekingalpha.com - September 12 at 8:45 PM
Here's Why Advaxis, Inc. Stock Is Getting Pummeled TodayHere's Why Advaxis, Inc. Stock Is Getting Pummeled Today
finance.yahoo.com - September 12 at 3:45 PM
10 Biggest Mid-Day Losers For Thursday10 Biggest Mid-Day Losers For Thursday
feeds.benzinga.com - September 12 at 2:28 PM
Heres Why Advaxis, Inc. Stock Is Getting Pummeled TodayHere's Why Advaxis, Inc. Stock Is Getting Pummeled Today
www.fool.com - September 12 at 1:57 PM
Advaxis, Inc. (ADXS) Announces Quarterly  Earnings ResultsAdvaxis, Inc. (ADXS) Announces Quarterly Earnings Results
www.americanbankingnews.com - September 12 at 9:22 AM
Advaxis reports 3Q lossAdvaxis reports 3Q loss
finance.yahoo.com - September 11 at 9:10 PM
Advaxis Reports Business Update and Third Quarter 2017 Results - Business Wire (press release)Advaxis Reports Business Update and Third Quarter 2017 Results - Business Wire (press release)
www.businesswire.com - September 11 at 4:07 PM
Advaxis Reports Business Update and Third Quarter 2017 ResultsAdvaxis Reports Business Update and Third Quarter 2017 Results
finance.yahoo.com - September 11 at 4:06 PM
What Does Advaxis Inc’s (ADXS) Share Price Indicate?What Does Advaxis Inc’s (ADXS) Share Price Indicate?
finance.yahoo.com - September 8 at 8:56 PM
Advaxis to Present at Third CRI-CIMT-EATI-AACR International ... - Business Wire (press release)Advaxis to Present at Third CRI-CIMT-EATI-AACR International ... - Business Wire (press release)
www.businesswire.com - August 2 at 8:31 PM
Advaxis to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into SurvivalAdvaxis to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
finance.yahoo.com - August 2 at 3:27 PM
Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry LeadersAdvaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders
finance.yahoo.com - July 13 at 4:09 PM
Advaxis (ADXS) CEO, President and Board Member, Daniel OConnor to Resign; Anthony Lombardo to Assume Interim CEO RoleAdvaxis (ADXS) CEO, President and Board Member, Daniel O'Connor to Resign; Anthony Lombardo to Assume Interim CEO Role
www.streetinsider.com - July 8 at 3:16 PM
Cantor Fitzgerald Reiterates "$19.00" Price Target for Advaxis, Inc. (NASDAQ:ADXS)Cantor Fitzgerald Reiterates "$19.00" Price Target for Advaxis, Inc. (NASDAQ:ADXS)
www.americanbankingnews.com - July 7 at 6:56 PM
Stocks To Watch For July 7, 2017 - BenzingaStocks To Watch For July 7, 2017 - Benzinga
www.benzinga.com - July 7 at 5:14 PM
Pre-Open Movers 07/07: (DGLY) (SNCR) (CLB) Higher; (CHKE) (RSYS) (ADXS) Lower (more...) - StreetInsider.comPre-Open Movers 07/07: (DGLY) (SNCR) (CLB) Higher; (CHKE) (RSYS) (ADXS) Lower (more...) - StreetInsider.com
www.streetinsider.com - July 7 at 5:14 PM
After-Hours Movers 07/06: (SNCR) (CLB) (DGSE) Higher; (CHKE) (RSYS) (ADXS) Lower (more...) - StreetInsider.comAfter-Hours Movers 07/06: (SNCR) (CLB) (DGSE) Higher; (CHKE) (RSYS) (ADXS) Lower (more...) - StreetInsider.com
www.streetinsider.com - July 7 at 2:58 AM
Advaxis (ADXS) CEO, President and Board Member, Daniel OConnor to Resign; Anthony Lombardo to Assume Interim ... - StreetInsider.comAdvaxis (ADXS) CEO, President and Board Member, Daniel O'Connor to Resign; Anthony Lombardo to Assume Interim ... - StreetInsider.com
www.streetinsider.com - July 7 at 2:58 AM
Advaxis Announces Change in LeadershipAdvaxis Announces Change in Leadership
finance.yahoo.com - July 6 at 4:52 PM
Advaxis CEO Daniel OConnor resignsAdvaxis CEO Daniel O'Connor resigns
finance.yahoo.com - July 6 at 4:52 PM

SEC Filings

Advaxis (NASDAQ:ADXS) SEC Filings

DateFilerForm TypeView
12/04/2017
3:30 PM
Advaxis (Issuer)
Bonstein Sara (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing
12/04/2017
3:30 PM
Advaxis (Issuer)
PETIT ROBERT (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
View Filing

Social Media

Financials

Advaxis (NASDAQ:ADXS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Advaxis (NASDAQ ADXS) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.